Business
‘Groundbreaking approach’: Imugene deal looks to smash solid tumours – Sydney Morning Herald
The $1.5 billion biotech will work with Nasdaq-listed firm Celularity in hopes of cracking the mystery of how to target tough…
Imugene, the cancer treatment maker chaired by biotech veteran Paul Hopper, is banking on a partnership with Nasdaq-listed biotech Celularity to unlock a revolutionary treatment that will obliterate solid tumours.
The Sydney-based company, which has seen…
Continue Reading